Activating Native Tumor Immunity with IL-33 Armored CARs

使用 IL-33 装甲 CAR 激活天然肿瘤免疫

• 批准号: 10744438
• 负责人: Yina Hsing Huang
• 金额: $ 57.35万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10744438
• 关键词: Adoptive Transfer; Antigen Receptors; Antigen Targeting; Antigens; Antitumor Response; Autoimmune Diseases; CAR T cell therapy; CCR5 gene; CXCR6 gene; Cell Survival; Cells; Clinic; Colon; Colon Carcinoma; Cytokine Receptors; Drug or chemical Tissue Distribution; Effector Cell; Flow Cytometry; HIF1A gene; Image; Immune; Immunomodulators; Immunosuppression; Immunotherapy; Infiltration; Interferon Type II; Interleukin-12; Interleukin-2; Investigation; Kinetics; Leukocytes; Liquid substance; MC38; MHC Class I Genes; Macrophage; Malignant Epithelial Cell; Malignant Neoplasms; Mediating; Metastatic Melanoma; Methods; Modeling; Molecular; Myeloid Cells; Natural Killer Cells; Nature; Pathway Analysis; Peptide/MHC Complex; Peripheral; Population; Race; Regulatory T-Lymphocyte; Reporting; Role; Safety; Solid; Solid Neoplasm; Spatial Distribution; T-Lymphocyte; Testing; Tissues; Toxic effect; Tumor Immunity; Tumor-associated macrophages; anti-tumor immune response; cancer immunotherapy; cancer therapy; chemokine receptor; chimeric antigen receptor; chimeric antigen receptor T cells; clinical translation; cytokine; delivery vehicle; draining lymph node; effector T cell; immunogenic; improved; in vivo; luminescence; lung metastatic; mouse model; neoantigens; neoplastic cell; novel; perforin; recruit; trafficking; transcriptomics; tumor; tumor growth; tumor microenvironment; tumor-immune system interactions

ABSTRACT Unlike liquid cancers, current CAR T cell immunotherapies have little effect against solid cancers, largely due to the immunosuppressive nature of the tumor microenvironment. The race between administered CAR T cells and tumor associated cells to kill off and/or neutralize the other is tipped heavily in favor of the tumor. Heterogeneous tumors or tumors able to shed or downregulate CAR-targeted antigens can also escape elimination by functional CAR T cell effectors. We recently found that CAR T cells delivery of dual cytokines can enlist and activate endogenous T cells, NK cells and myeloid cells to mount an effective anti-tumor immune response. Further investigation revealed that perforin and IFNγ are dispensable in CAR T cells, supporting an accessory role for CAR T cells in mobilizing endogenous immune cells to ultimately control tumor growth. CAR T cell-mediated dual cytokine delivery was effective in controlling tumor growth with 3 different CAR T cell constructs and 4 in vivo tumor models: primary and metastatic melanoma and primary colon cell carcinoma mouse models, and importantly was impervious to antigen loss. This suggests that the dual cytokine platform has potential for universal application against multiple solid tumor types. In this application, we hypothesize that CAR T cell delivery of dual cytokines has broad application because it counteracts immunosuppressive innate and adaptive immune cells to elicit a broad endogenous anti-tumor response independent of CAR effector potential. We will test this hypothesis by identifying CAR T cell survival and distribution dynamics (Aim 1), identify the common and tumor-specific changes in immunosuppressive, immunostimulatory and effector leukocyte populations isolated from poorly and strongly immunogenic tumors pre- and post-CAR cytokine treatment (Aim 2), and determine their roles in activating endogenous tumor immunity (Aim 3). The cellular and mechanisms identified will support further improvement and clinical translation of the Super2+IL-33 platform with various CAR targeting constructs for CAR T cell therapies for solid tumors.

摘要 与液体癌症不同，目前的CAR T细胞免疫疗法对实体癌症几乎没有效果，这主要是由于 肿瘤微环境的免疫抑制性质。给予的CAR T细胞和 肿瘤相关细胞杀死和/或中和另一种的倾向严重有利于肿瘤。异构 肿瘤或能够脱落或下调CAR靶向抗原的肿瘤也可以通过功能性免疫抑制而逃避消除。 CAR T细胞效应子。我们最近发现，CAR T细胞递送双重细胞因子可以招募和激活 在一些实施方案中，免疫抑制剂可以包括内源性T细胞、NK细胞和骨髓细胞，以产生有效的抗肿瘤免疫应答。进一步 研究表明，穿孔素和IFNγ在CAR T细胞中是可有可无的，支持其辅助作用 CAR T细胞动员内源性免疫细胞，最终控制肿瘤生长。CAR T细胞介导 双重细胞因子递送在控制肿瘤生长方面是有效的，用3种不同的CAR T细胞构建体和4种不同的CAR T细胞构建体。 体内肿瘤模型：原发性和转移性黑素瘤和原发性结肠细胞癌小鼠模型，和 重要的是不受抗原损失的影响。这表明双重细胞因子平台具有潜在的 普遍适用于多种实体瘤类型。在本申请中，我们假设CAR T细胞 双重细胞因子的递送具有广泛的应用，因为它抵消了先天性和适应性免疫抑制 在一些实施方案中，CAR可以与免疫细胞结合，以引起广泛的内源性抗肿瘤应答，而不依赖于CAR效应子潜力。我们将 通过鉴定CAR T细胞存活和分布动力学来测试这一假设（目的1）， 以及免疫抑制、免疫刺激和效应白细胞群的肿瘤特异性变化 从CAR细胞因子治疗前和治疗后的免疫原性差和免疫原性强的肿瘤中分离（Aim 2），和 确定它们在激活内源性肿瘤免疫中的作用（目的3）。细胞和机制确定 将支持具有各种CAR靶向的Super 2 +IL-33平台的进一步改进和临床转化 用于实体瘤的CAR T细胞疗法的构建体。